Dimensional Fund Advisors LP Acquires 3,889 Shares of USANA Health Sciences, Inc. (NYSE:USNA)

Dimensional Fund Advisors LP boosted its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 0.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 683,158 shares of the company’s stock after acquiring an additional 3,889 shares during the period. Dimensional Fund Advisors LP’s holdings in USANA Health Sciences were worth $30,907,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. CWM LLC increased its position in shares of USANA Health Sciences by 21.8% during the first quarter. CWM LLC now owns 1,543 shares of the company’s stock valued at $75,000 after buying an additional 276 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of USANA Health Sciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after acquiring an additional 494 shares during the period. State Board of Administration of Florida Retirement System raised its position in shares of USANA Health Sciences by 22.7% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock worth $409,000 after acquiring an additional 1,560 shares in the last quarter. First Hawaiian Bank lifted its stake in shares of USANA Health Sciences by 22.3% in the 1st quarter. First Hawaiian Bank now owns 9,089 shares of the company’s stock valued at $441,000 after purchasing an additional 1,656 shares during the period. Finally, BOKF NA boosted its position in shares of USANA Health Sciences by 274.5% during the first quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after purchasing an additional 2,031 shares in the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. DA Davidson dropped their price objective on shares of USANA Health Sciences from $46.00 to $38.00 and set a “neutral” rating on the stock in a research note on Thursday, July 25th. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

USANA Health Sciences Trading Down 1.7 %

USNA stock opened at $37.26 on Wednesday. The stock has a market capitalization of $709.80 million, a PE ratio of 11.60, a price-to-earnings-growth ratio of 1.27 and a beta of 0.90. The stock’s 50 day simple moving average is $39.85 and its 200 day simple moving average is $43.94. USANA Health Sciences, Inc. has a 12-month low of $36.05 and a 12-month high of $59.85.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.11). USANA Health Sciences had a net margin of 6.29% and a return on equity of 11.13%. The company had revenue of $212.87 million for the quarter, compared to analysts’ expectations of $218.64 million. During the same period in the previous year, the firm earned $0.89 earnings per share. On average, research analysts predict that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current year.

Insider Activity at USANA Health Sciences

In other USANA Health Sciences news, Director John Turman Fleming sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, Director John Turman Fleming sold 1,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total value of $44,430.00. Following the transaction, the director now directly owns 2,503 shares in the company, valued at $111,208.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is owned by company insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.